First SphygmoCor sales in China

THE ROADHOUSE PHARMACY: AtCor Medical (ASX: ACG), the developer and marketer of the SphygmoCor® system which measures central aortic blood pressures and arterial stiffness noninvasively, has received its first order for SphygmoCor XCEL systems from its Chinese distributor, Angy (China) Medical Ltd.

The company said the initial order, for 11 SphygmoCor systems, follows the launch of AtCor’s new product at the China International Medical Equipment Fair in Shenzhen in April this year.
 
“We are delighted that Angy Medical has capitalised on the introduction of SphygmoCor XCEL to China with this sale, which follows closely the product’s clearance through the Chinese regulatory process,” AtCor Medical CEO and president Duncan Ross said in the company’s announcement to the Australian Securities Exchange.

“It establishes a beachhead for AtCor in the Chinese market where awareness of hypertension is growing.”

AtCor explained clinical evidence that central blood pressure measurement, as measured by the SphygmoCor system, is a stronger predictor of cardiovascular events is now well established.

The company claims SphygmoCor XCEL helps detect cardiovascular diseases earlier, optimises medication for patients with hypertension, and provides the most sophisticated software for central blood pressure management today.

Website: www.atcormedical.com